468
Views
17
CrossRef citations to date
0
Altmetric
Review

The cost-effectiveness of therapies to treat alcohol use disorders

&
Pages 43-49 | Received 14 Sep 2017, Accepted 11 Oct 2017, Published online: 20 Oct 2017

References

  • GBD. 2016 Risk factors collaborators. Global, regional, and national comparative risk assessment of 84 behavioral, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390:1345–1422.
  • World Health Organization. Global status report on alcohol and health. Geneva, Switzerland: World Health Organization; 2014.
  • Rehm J, Imtiaz S. Alcohol consumption as a risk factor for global burden of disease. A narrative review. Subst Abuse Treat Prev Policy. 2016;11:37.
  • Rehm J, Shield KD, Rehm MX, et al. Modelling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union. Eur Neuropsychopharmacol. 2013;23:89–97.
  • Schwarzinger M, Thiébaut SP, Baillot S, et al. Alcohol use disorders and associated chronic disease - a national retrospective cohort study from France. BMC Public Health. 2018;18:43.
  • Westman J, Wahlbeck K, Laursen TM, et al. Mortality and life expectancy of people with alcohol use disorder in Denmark, Finland and Sweden. Acta Psychiat Scand. 2015;131:297–306.
  • Anderson P, Braddick F, Conrod P, et al. The new governance of addictive substances and behaviours. Oxford, U.K.: Oxford University Press; 2017.
  • Rehm J, Shield KD, Rehm MX, et al. Alcohol consumption, alcohol dependence, and attributable burden of disease in Europe: potential gains from effective interventions for alcohol dependence. Toronto, Canada: Centre for Addiction and Mental Health; 2012.
  • Caetano R, Cunradi C. Alcohol dependence: a public health perspective. Addiction. 2002;97:633–645.
  • Berglund M, Thelander S, Jonsson E. Treating alcohol and drug abuse. An evidenced based review. Weinheim, Germany: Wiley-VCH Verlag; 2003.
  • Hester RK, Miller WR. Handbook of alcoholism treatment approaches. Effective alternatives. 3rd ed. Boston USA: Allyn & Bacon; 2003.
  • Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311:1889–1900.
  • Kenna GA, Leggio L. Alcohol use disorder. In: MacKillop J, Kenna GA, Leggio L, et al., editors. integrating psychological and pharmacological treatments for addictive disorders. New York, NY: Routledge; 2018. p. 77–98.
  • Cohen E, Feinn R, Arias A, et al. Alcohol treatment utilization: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend. 2007;86:214–221.
  • Kohn R, Saxena S, Levav I, et al. The treatment gap in mental health care. Bull World Health Org. 2004;82:858–866.
  • Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. New York, NY: Oxford University Press; 2005.
  • Connor JP, Haber PS, Hall W. Alcohol use disorders. Lancet. 2015;387:988–998.
  • Schuckit MA. Alcohol-use disorders. Lancet. 2009;373:492–501.
  • Rehm J, Manthey J, Struzzo P, et al. Who receives treatment for alcohol use disorders in the European Union? A cross-sectional representative study in primary and specialized health care. Euro Psych. 2015;30:885–893.
  • World Health Organization. The ICD-10 classification of mental and behavioral disorders: diagnostic criteria for research. Geneva: World Health Organization; 1993.
  • American Psychiatric Association. Substance use and addiction-related disorders. In: Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Association,; 2013. p. 481–589.
  • Rehm J, Allamani A, Elekes Z, et al. General practitioners recognizing alcohol dependence: a large cross-sectional study in six European countries. Ann Fam Med. 2015;13:28–32.
  • Rehm J, Room R. Cultural specificity in alcohol use disorders. Lancet. 2015 Sep 3. pii: S0140-6736(15)00123-3. doi: 10.1016/S0140-6736(15)00123-3. [Epub ahead of print].
  • Rehm J, Room R. The cultural aspect: how to measure and interpret epidemiological data on alcohol use disorders across cultures. Nordisk Alkohol Nark. 2017;34:330–341.
  • McHugh RK, Hearon BA, Otto MW. Cognitive-Behavioral Therapy for substance use disorders. Psychiatr Clin North Am. 2010;33:511–525.
  • Rösner S, Hackl-Herrwerth A, Leucht S, et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;9:CD004332.
  • Rösner S, Hackl-Herrwerth A, Leucht S, et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;12:CD001867.
  • Leucht S, Helfer B, Gartlehner G, et al. How effective are common medications: a perspective based on meta-analyses of major drugs. BMC Med. 2015;13:253.
  • MacKillop J, Kenna GA, Leggio L, et al. Integrating psychological and pharmacological treatments for addictive disorders. New York, NY: Routledge; 2018.
  • Sher KJ. The Oxford Handbook of Substance use and substance use disorders. New York, NY: Oxford University Press; 2016.
  • Ghodse H, Herrman H, Maj M, et al. Substance Abuse Disorders. West Sussex, UK: Wiley-Blackwell; 2011.
  • Becker P, Kayo M. Cost-effectiveness of interventions for the treatment of alcohol and other substance use disorders. In: Razzouk D, editor. Mental health economics. London, UK: Springer International Publishing; 2017. p. 323–338.
  • Angus C, Latimer N, Preston L, et al. What are the implications for policy makers? A systematic review of the cost-effectiveness of screening and brief interventions for alcohol misuse in primary care. Front Psychiatry. 2014;5:114.
  • Jonas DE, Garbutt JC, Amick HR, et al. Behavioral counseling after screening for alcohol misuse in primary care: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2012;157:645–654.
  • Solberg LI, Maciosek MV, Edwards NM. Primary care intervention to reduce alcohol misuse ranking its health impact and cost effectiveness. Am J Prev Med. 2008;34:143–152.
  • Taguchi Y, Yoshimoto H, Ikeda S. Considerations of screening and brief intervention among high-risk drinkers in Japan: from the perspectives of feasibility and cost-effectiveness. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2016;51:13–25.
  • Barbosa C, Godfrey C, Parrott S. Methodological assessment of economic evaluations of alcohol treatment. What is missing? Alcohol Alcohol. 2010;45:53–63.
  • Suijkerbuijk AW, Van Gils PF, Greeven PG, et al. De kosteneffectiviteit van interventies gericht op verslaving aan alcohol en drugs. [Cost-effectiveness of addiction care]. Tijdschrift Voor Psychiatrie. 2015;57:498–507.
  • Palmer A, Neeser K, Weiss C, et al. The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate. Alcohol Alcohol. 2000;35:478–492.
  • Walters D, Connor JP, Feeney GF, et al. The cost effectiveness of naltrexone added to cognitive-behavioral therapy in the treatment of alcohol dependence. J Addict Disord. 2009;28:137–144.
  • Heather N, Copello A, Godfrey C, et al. Cost-effectiveness of treatment for alcohol problems: findings of the randomised UK Alcohol Treatment Trial (UKATT). Bmj. 2005;331:544.
  • Sassi F, Cecchini M, Deveaux M, et al. Health and economic impacts of key alcohol policy options. In: Sassi F, editor. Tackling harmful alcohol use. Paris, France: OECD; 2015. p. 141–180.
  • World Health Organization. Cost effectiveness and strategic planning. 2017 [cited 2017 Aug 17]. Available from: http://www.who.int/choice/en/.
  • Chisholm D, Doran C, Shibuya K, et al. Comparative cost-effectiveness of policy instruments for reducing the global burden of alcohol, tobacco and illicit drug use. Drug Alcohol Rev. 2006;25:553–565.
  • Chisholm D, Rehm J, van Ommeren M, et al. Reducing the global burden of hazardous alcohol use: a comparative cost-effectiveness analysis. J Stud Alcohol. 2004;65:782–793.
  • World Health Organization. Draft - Updated Appendix 3 of the WHO Global NCD Action Plan 2013-2020. [ cited 2017 Aug 16]. Available from: http://who.int/ncds/governance/discussion-paper-updating-appendix3-25july2016-EN.pdf.
  • World Health Organization. Global action plan for the prevention and control of NCDs 2013-2020. Geneva, Switzerland: World Health Organization; 2013.
  • Holder H, Longabaugh R, Miller WR, et al. The cost effectiveness of treatment for alcoholism: a first approximation. J Stud Alcohol. 1991;52:517–540.
  • Finney J, Monahan S. The cost-effectiveness of treatment for alcoholism: a second approximation. J Stud Alcohol. 1996;57:229–243.
  • Howard MO. Assessing the comparative cost-effectiveness of alcoholism treatments: a comment on Holder, Longabaugh, Miller and Rubonis. J Stud Alcohol. 1993;54:667–675.
  • Slattery J, Chick J, Cochrane M, et al. Prevention of relapse in alcohol dependence. Glasgow, Scotland: Scotland HTBf; 2003.
  • Holder HD. The cost offsets of alcoholism treatment. Recent Dev Alcohol. 1998;14:361–374.
  • Holder HD. Cost benefits of substance abuse treatment: an overview of results from alcohol and drug abuse. J Ment Health Policy Econ. 1998;1:23–29.
  • Holder HD, Blose JO. The reduction of health care costs associated with alcoholism treatment: a 14-year longitudinal study. J Stud Alcohol. 1992;53:293–302.
  • Blose JO, Holder HD. The utilization of medical care by treated alcoholics: longitudinal patterns by age, gender, and type of care. J Subst Abuse. 1991;3:13–27.
  • Holder HD, Blose JO. Changes in health care costs and utilization associated with mental health treatment. Hosp Community Psychiatry. 1987;38:1070–1075.
  • Holder HD, Hallan JB. Impact of alcoholism treatment on total health care costs: a six-year study. Adv Alcohol Subst Abuse. 1986;6:1–15.
  • Holder HD, Cisler RA, Longabaugh R, et al. Alcoholism treatment and medical care costs from Project MATCH. Addiction. 2000;95:999–1013.
  • UKATT Research Team. United Kingdom Alcohol Treatment Trial (UKATT): hypotheses, design and methods. Alcohol Alcohol. 2001;36:11–21.
  • Zarkin GA, Bray JW, Aldridge A, et al. Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients. Arch Gen Psychiatry. 2008;65:1214–1221.
  • Dunlap LJ, Zarkin GA, Bray JW, et al. Revisiting the cost-effectiveness of the COMBINE study for alcohol dependent patients: the patient perspective. Medical Care. 2010;48:306–313.
  • Anton R, O’Malley S, Ciraulo D, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence. The COMBINE study: a randomized controlled trial. JAMA. 2006;17:2003–2017.
  • Mann K, Torup L, Sørensen P, et al. Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. Eur Neuropsychopharmacol. 2016;26:1941–1949.
  • Laramée P, Brodtkorb TH, Rahhali N, et al. The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol dependent patients with high/very high drinking risk levels: a Markov model. BMJ Open. 2014;4:e005376.
  • Laramée P, Millier A, Brodtkorb TH, et al. A comparison of Markov and discrete-time microsimulation approaches: simulating the avoidance of alcohol-attributable harmful events from reduction of alcohol consumption through treatment of alcohol dependence. Clinical Drug Investigation. 2016;36:945–956.
  • Organisation for Economic Co-operation and Development. Tackling harmful alcohol use: economics and public health policy. Paris: Organisation for Economic Co-operation and Development; 2015.
  • Rehm J, Dawson D, Frick U, et al. Burden of disease associated with alcohol use disorders in the United States. Alcohol Clin Exp Res. 2014;38:1068–1077.
  • Rehm J, Allamani A, Elekes Z, et al. Alcohol dependence and treatment utilization in Europe - a representative cross-sectional study in primary care. BMC Fam Prac. 2015;16:90.
  • Kraus L, Piontek D, Pfeiffer-Gerschel T, et al. Inanspruchnahme gesundheitlicher versorgung durch alkoholabhängige [health care utilization of people with alcohol dependence]. Suchtherapie. 2015;16:18–26.
  • Lui S, Terplan M, Smith EJ. Psychosocial interventions for women enrolled in alcohol treatment during pregnancy. Cochrane Database Syst Rev. 2008;16:CD06753.
  • Morley KC, Teesson M, Reid SC, et al. Natrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomised, double-blined, placebo-controlled trial. Addiction. 2006;101:1451–1462.
  • Baltieri DA, Guerra De Andrade A. Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting. J Stud Alcohol. 2004;65:136–139.
  • Anderson P, Møller L, Galea G. Alcohol in the European Union: consumption, harm and policy approaches. Copenhagen: World Health Organization; 2012.
  • Mason BJ, Goodman AM, Chabac S, et al. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res. 2006;40:383–393.
  • Roozen HG, de Waart R, van der Windt DA, et al. A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. Eur Neuropsychopharmacol. 2006;16:311–323.
  • Purshouse CR, Meier PS, Brennan A, et al. Estimated effect of alcohol pricing policies on health and health economic outcomes in England: an epidemiological model. Lancet. 2010;375:1355–1364.
  • Babor T, Caetano R, Casswell S, et al. Alcohol: no ordinary commodity. Research and public policy. 2nd. Oxford and London: Oxford University Press; 2010.
  • Anderson P, Chisholm D, Fuhr D. Effectiveness and cost-effectiveness of policies and programmes to reduce the harm caused by alcohol. Lancet. 2009;373:2234–2246.
  • Babor TF, Higgins-Biddle JC. Brief Intervention - For hazardous and harmful drinking. In: A manual for use in primary care. Geneva, Switzerland: World health Organization; 2001.
  • Babor T, Higgins-Biddle J, Saunders J, et al. AUDIT - The alcohol use disorders identification test: guidelines for use in primary care. 2 ed. Geneva: World Health Organization; 2001.
  • Kaner EF, Beyer F, Dickinson HO, et al. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev. 2007;18:CD004148.
  • Álvarez-Bueno C, Rodríguez-Martín B, García-Ortiz L, et al. Effectiveness of brief interventions in primary health care settings to decrease alcohol consumption by adult non-dependent drinkers: a systematic review of systematic reviews. Prev Med. 2015;76(Suppl):S33–S8.
  • McQueen J, Howe TE, Allan L, et al. Brief interventions for heavy alcohol users admitted to general hospital wards. Cochrane Database Syst Rev. 2011;8:CD005191.
  • Barbosa C, Cowell A, Bray J, et al. The cost-effectiveness of alcohol Screening, Brief Intervention, and Referral to Treatment (SBIRT) in emergency and outpatient medical settings. J Subst Abuse Treat. 2015;53:1–8.
  • Barbosa C, Cowell A, Dowd W, et al. The cost-effectiveness of brief intervention versus brief treatment of Screening, Brief Intervention and Referral to Treatment (SBIRT) in the United States. Addiction. 2017;112 Suppl 2:73–81.
  • Angus C, Thomas C, Anderson P, et al. Estimating the cost-effectiveness of brief interventions for heavy drinking in primary health care across Europe. Eur J Public Health. 2017;27:345–351.
  • Anderson P, Bendtsen P, Spak F, et al. Improving the delivery of brief interventions for heavy drinking in primary health care: outcome results of the Optimizing Delivery of Health Care Intervention (ODHIN) five-country cluster randomized factorial trial. Addiction. 2016;111:1935–1945.
  • Colom J, Scafato E, Segura L, et al. Brief interventions implementation on alcohol from the European health systems perspective. Front Psychiatry. 2014;5:161.
  • Nilsen P. Brief alcohol intervention-where to from here? Challenges remain for research and practice. Addiction. 2010;105:954–959.
  • Drummond C, Wolstenholme A, DeLuca P, et al. Alcohol interventions and treatments in Europe. Anderson P, Braddick F, Reynolds J, et al., editors. Alcohol Policy in Europe: evidence from AMPHORA. 2nd ed. Barcelona:AMPHORA; 2013. p.65–80.
  • Johnson M, Jackson R, Guillaume L, et al. Barriers and facilitators to implementing screening and brief intervention for alcohol misuse: a systematic review of qualitative evidence. J Public Health. 2011;33:412–421.
  • Probst C, Manthey J, Martinez A, et al. Alcohol use disorder severity and reported reasons not to seek treatment: a cross-sectional in European primary care practices. Subst Abuse Treat Prev Policy. 2015;10:32.
  • Wallhed Finn S, Bakshi AS, Andreasson S. Alcohol consumption, dependence, and treatment barriers: perceptions among nontreatment seekers with alcohol dependence. Subst Use Misuse. 2014;49:762–769.
  • Rehm J, Anderson P, Arbesu Prieto JA, et al. Towards new recommendations to reduce the burden of alcohol-induced hypertension in the European Union. BMC Med. 2017;15:173.
  • McCambridge J, Rollnick S. Should brief interventions in primary care address alcohol problems more strongly? Addiction. 2014;109:1054–1058.
  • McCambridge J, Saitz R. Rethinking brief interventions for alcohol in general practice. Bmj. 2017;356:j116.
  • Rehm J, Anderson P, Manthey J, et al. Alcohol use disorders in primary health care – what do we know and where do we go? Alcohol Alcohol. 2015;51:422–427.
  • Schomerus G, Lucht M, Holzinger A, et al. The stigma of alcohol dependence compared with other mental disorders: a review of population studies. Alcohol Alcohol. 2011;46:105–112.
  • Rehm J, Mathers C, Popova S, et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol use disorders. Lancet. 2009;373:2223–2233.
  • Shield KD, Rehm MX, Rehm J. Social costs of addiction in Europe. In: Anderson P, Rehm J, Room R, editors. The impact of addictive substances and behaviours on individual and societal well-being. Oxford, UK: Oxford University Press; 2015. p. 181–188.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.